🏭 The facility specializes in sterile injectables and will gain 24,000 sq ft of space and new machinery.
📈 This expansion aims to boost production capacity from 104 to 240 batches per year by Q1 2027.
💊 It positions Piramal as a significant player in the growing injectables market.
Introduction:
The article discusses Piramal Pharma Solutions’ (PPS) announcement of an $80 million investment to expand its Lexington, Kentucky facility, which specializes in the production of sterile injectable drug products. This strategic expansion is primarily focused on meeting the increasing demand in the rapidly growing injectables market.
- Piramal Pharma Solutions plans to invest $80 million to enhance its Lexington, KY facility, which is crucial for sterile compounding and manufacturing initiatives.
- The forthcoming expansion will add 24,000 square feet of manufacturing space and upgrade technology, including a new filling line and advanced lyophilizers.
- Post-expansion, the facility’s production capacity will more than double, increasing from 104 to over 240 product batches annually by Q1 2027.
- The expansion aims to bridge the commercial manufacturing gap in the injectables market, which is projected to surpass a market value of $20 billion by 2028.
- Key company leaders emphasized that the expansion positions Piramal Pharma as a significant player in the injectables segment, aiming to address current supply shortages amid rising patient needs.
Conclusion:
The investment by Piramal Pharma Solutions signifies a proactive approach to meet the surging demand for injectables, driven by advancements in treatment efficacy and patient care. This expansion enhances the company’s capabilities to cater to various stages of the product lifecycle, ultimately benefiting a larger patient population through improved treatment access.
